CRVS Corvus Pharmaceuticals

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET. 

A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the section of the Corvus website. 

About Corvus Pharmaceuticals 

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit . 

INVESTOR CONTACT: 

Leiv Lea 

Chief Financial Officer 

Corvus Pharmaceuticals, Inc. 

 

  

MEDIA CONTACT: 

Sheryl Seapy 

Real Chemistry 



EN
31/10/2025

Underlying

CRVSCorvus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corvus Pharmaceuticals

 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthc...

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET.  A webcast of the fireside cha...

October 31, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 20...

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results.   The conference call can be accessed by dialing 1-800-717-1...

October 28, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Announces Presentation of Interim Data from the...

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab is feasible and well tolerated; longer follow-up with patients still on therapy needed to determine potential bene...

October 17, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Corvus Pharmaceuticals Appoints David Moore to Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company’s Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development and investing from ...

October 2, 2025 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Provides Business Update and Reports Second Qua...

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension cohort 4 exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period; Phase 2 trial on track to initiate before end of year Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T ce...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch